Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation PARIS, France, October 7, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, is thrilled to extend heartfelt congratulations to Victor Ambros and Gary Ruvkun for being awarded the Nobel Prize in Physiology or Medicine.
Their groundbreaking work in the field of microRNA has significantly advanced our understanding of gene regulation and its implications for human health. Marc de Garidel, CEO of Abivax, said, “The recognition of Ambros and Ruvkun underscores the importance of microRNA research and its potential to transform therapeutic approaches”. He went on to say “At Abivax, we are proud to be at the forefront of innovative therapies that harness the power of microRNAs.
Our lead candidate, obefazimod, which is currently being evaluated in a Phase 3 Trial clinical program for Ulcerative Colitis and a Phase 2B Trial for Crohn’s Disease, acts by enhancing expression of microRNA-124 (miR-124), which stabilizes inflammatory pathways to reduce inflammation in patients with chronic inflammatory conditions.” Didier Scherrer, Chief Scientific Officer at Abivax ,.
